Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 8Gynecologic 4Genitourinary 3Thoracic 2Gastrointestinal 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1CNS 1

Conditions

Pancreatic Neoplasms 4Colorectal Neoplasms 3Stomach Neoplasms 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasm Metastasis 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Sarcoma 1Primary Myelofibrosis 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lung Neoplasms 1Leukemia 1Leiomyosarcoma 1Glioblastoma 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Carcinoma, Non-Small-Cell Lung 1Biliary Tract Neoplasms 1Advanced Gastric Cancer 1

Interventions

pembrolizumab 36Capecitabine 28Trastuzumab 23Paclitaxel 22Surveys and Questionnaires 20Cyclophosphamide 20Gemcitabine 18Docetaxel 18Carboplatin 15Nivolumab 14Methods 14Magnetic Resonance Spectroscopy 13Early Intervention, Educational 13Bevacizumab 13Interviews as Topic 12Blood Specimen Collection 12fludarabine 11Standard of Care 11Irinotecan 11olaparib 10durvalumab 10Specimen Handling 10Psychiatric Rehabilitation 10palbociclib 9aldesleukin 9Taxes 9Fulvestrant 9Fluorouracil 9Exercise 9Drug Therapy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasms × rucaparib × Gastrointestinal × Clear all
NCT02711137 2025-10-21

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Incyte Corporation

Phase 1/2 Terminated
137 enrolled 31 charts
BreastCNSGastrointestinalGenitourinaryGynecologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Primary Myelofibrosis

NCT04171700 2023-10-02

LODESTAR

pharmaand GmbH

Phase 2 Terminated
83 enrolled 16 charts
BreastGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinosarcoma, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Leiomyosarcoma, Lung Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡